Anti-pre-ART SIV efficacy of CD8+ cells under ART (at week 27) was significantly correlated with Gag-specific CD8+ T-cell responses (R = 0.9429, P = 0.0167 by Spearman test) but not with Vif-specific CD8+ T-cell responses at week 27 post-infection (1 week after the first vaccination) (Fig. 5). The gene discussed is CD8A; the disease is infection.